Press releases

2013

15/05/2013
ABLYNX ANNOUNCES Q1 2013 BUSINESS UPDATE


08/05/2013
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")


07/05/2013
ABLYNX STARTS PRE-CLINICAL DEVELOPMENT OF ALX-0962, AN ANTI-IgE NANOBODY, TO TREAT SEVERE ALLERGIC ASTHMA


22/04/2013
ABLYNX ANNOUNCES WARRANT EXERCISE


17/04/2013
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")


26/03/2013
NOTICE OF ABLYNX'S ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS


08/03/2013
PUBLICATION IN ACCORDANCE WITH ARTICLES 14 AND 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")


28/02/2013
ABLYNX SUCCESSFULLY RAISES €31.5 MILLION, IN TOTAL €45 MILLION PLACED


27/02/2013
ABLYNX TO RAISE CAPITAL VIA A PRIVATE PLACEMENT OF NEW SHARES


27/02/2013
ABLYNX ANNOUNCES 2012 FULL YEAR RESULTS


25/02/2013
ABLYNX AND SPIROGEN ENTER INTO A RESEARCH COLLABORATION TO EVALUATE THE POTENTIAL OF NOVEL TOXIN-NANOBODY DRUG CONJUGATES IN CANCER


20/02/2013
ABLYNX PROMOTED TO THE BELGIAN MID-CAP INDEX


13/02/2013
ABLYNX'S ANTI-IL-6R NANOBODY, ALX-0061, SHOWS EXCELLENT 24 WEEK SAFETY AND EFFICACY RESULTS IN A PHASE II CLINICAL TRIAL IN RHEUMATOID ARTHRITIS


21/01/2013
ABLYNX ANNOUNCES WARRANT EXERCISE


07/01/2013
ABLYNX TO PRESENT AT 2013 J.P. MORGAN HEALTHCARE CONFERENCE